All In Biotech

Drug Trial Radar · NCT06215859

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

Multi-Center, Randomized, Double-Blind, Placebo (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 579 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

579

Actual

Start

Dec 29, 2023

Primary completion

Jan 31, 2025

Study completion Mar 12, 2025

Sponsor

Lead sponsor
Viatris Specialty LLCIndustry
Sponsor type
Industry
Collaborators
Mylan Specialty, LP
First posted
Jan 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.

Conditions

  • Acute Pain
  • Post Operative Pain
  • Pain

Interventions

  • MR-107A-02Drug

    tablet

  • TramadolDrug

    over-encapsulated tablet

  • PlaceboDrug

    over-encapsulated tablet and/or tablet

  • HerniorrhaphyProcedure

    Unilateral open inguinal herniorrhaphy with mesh under general anesthesia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summed Pain Intensity Difference (SPID) for MR-107A-02 versus placebo.Time frame: 48 hours after randomization

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator site 210

    Sheffield, Alabama

  • Investigator site 213

    Phoenix, Arizona

  • Investigator site 202

    Anaheim, California

  • Investigator site 222

    Bakersfield, California

  • Investigator site 208

    Riverside, California

  • Investigator site 211

    Miami, Florida

  • Investigator site 206

    Tampa, Florida

  • Investigator site 207

    Atlanta, Georgia

  • Investigator site 205

    Wichita, Kansas

  • Investigator site 212

    Bellaire, Texas

  • Investigator site 215

    Carrollton, Texas

  • Investigator site 204

    Houston, Texas

  • Investigator site 216

    McAllen, Texas

  • Investigator site 219

    San Antonio, Texas

  • Investigator site 203

    San Antonio, Texas

  • Investigator site 214

    San Antonio, Texas

  • Investigator site 201

    Salt Lake City, Utah

  • Investigator site 224

    Eau Claire, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.